Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial is designed to be a multi-center prospective, parallel-controlled Phase
III clinical study. In this study, the efficacy of tamoxifen versus toremifene shall be
compared in CYP2D6 intermediate/poor metabolizers of premenopausal patients with estrogen
receptor-positive early breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Chinese Anti-Cancer Association
Collaborators:
Affiliated Hospital of Qinghai University Cancer Institute and Hospital, Chinese Academy of Medical Sciences First Affiliated Hospital of Chongqing Medical University First Hospital of China Medical University First Hospital of Jilin University Fudan University Guangdong Provincial People's Hospital Hainan People's Hospital Harbin Medical University Hebei Tumor Hospital Henan Cancer Hospital Hunan Cancer Hospital Jiangsu Provincial People's Hospital Southwest Hospital, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University The First Hospital of Jilin University The Third Affiliated Hospital of Kunming Medical College. The Third Affiliated Hospital of Nanchang University Tianjin Medical University Cancer Institute and Hospital Union hospital of Fujian Medical University Wuhan TongJi Hospital Zhejiang Cancer Hospital